PD-RISK Index: Piloting an unsupervised toolkit to identify adults with Parkinson disease
Preprint
Abstract
Effective screening for Parkinson disease (PD) is important for symptom management and patient recruitment into disease-modifying trials. Here, we examined the performance of the PD-RISK Index toolkit in identifying PD patients at home without supervision. Between 2022-2024, we recruited 305 participants (ages, 40–85 years): 93 with typical PD; 66 had other neurological conditions; and 146 were healthy controls. Two versions of the toolkit were completed: An original, 69-item-long questionnaire with the 40-scent University-of-Pennsylvania-Smell-Identification-Test (UPSIT); thereafter, a simplified, 11-item-short questionnaire with a newly-developed 8-scent smell test and responses submitted online. The corresponding summary scores (‘PD-RISK Indices’) were calculated for each subject to evaluate diagnostic performances. In both versions, PD patients had higher questionnaire scores and worse olfaction than healthy controls ( P ), as expected; scores for subjects with other neurological conditions ranked at intermediate levels. The simplified 11-item questionnaire outperformed the original version in identifying PD. The abbreviated 8-scent smell test and the UPSIT booklet performed equally well in detecting hyposmia. The simplified PD-RISK Index showed the highest diagnostic performance in identifying PD patients amongst all participants; at a value of 23 (range, 0–100, where higher scores indicate higher PD risk), we measured a sensitivity of 0.98, specificity of 0.83, and positive and negative likelihood ratios of 5.88 and 0.02, respectively. The simplified ‘PD-RISK Index’ showed stable performance across sexes and disease duration. Our study reveals that unsupervised screening for manifest PD can be effectively carried out at home using an 11-item questionnaire, 8-scent smell test and online data entry. The plain language title: The PD-RISK Index study: Facilitating an earlier diagnosis of adults with Parkinson disease by screening at home with a short questionnaire and a simplified smell test Plain language summaries: Effective screening for Parkinson disease (PD) is important for symptom management by healthcare workers and the recruitment of patients into disease modifying trials. We previously published a two-step model for this purpose, which has been validated using several established study cohorts. The study below represents a field-test of this model and the toolkit to implement it (i.e. a self-report questionnaire and a smell test) using a real-world setting. Between 2022-2024, 305 participants (ages, 40-85 years) were recruited into the study: 93 with typical PD; 66 had other neurological conditions; 146 were healthy. Two versions of the toolkit were completed at-home without supervision by a healthcare worker: (1) an original , 69-item-long questionnaire and a 40-scent smell test; (2) a simplified , 11-item-short questionnaire with a newly created, 8-scent smell test. Accordingly, two versions of summary scores (‘PD-RISK Index’) were calculated for each subject to examine group classification. Several performance metrics were used to evaluate diagnostic performances and to suggest clinically relevant thresholds. In both versions, PD patients had significantly higher questionnaire scores (meaning higher risk of having PD) and lower smell test scores (meaning more impaired sense of smell) than healthy controls; scores for subjects with other neurological conditions ranked at intermediate levels. The simplified questionnaire outperformed the original version in diagnostic accuracy. The abbreviated smell test performed as well as the 40-item version in identifying hyposmia. The simplified ‘PD-RISK Index’ showed stable performance across sexes and disease duration. This study shows that non-invasive and unsupervised screening for manifest PD can be effectively carried out remotely using a simple 11-item questionnaire, an abbreviated 8-scent smell test and an online data entry system, thereby generating a PD-RISK Index for each individual.Keywords
Funding Information
- Parkinson Research Consortium Ottawa
- uOttawa Brain & Mind Research Institute
- Department of Medicine, University of Ottawa
- Uttra & Subash Bhargava Family
- Aligning Science Across Parkinson's (ASAP-020625)
This publication has 48 references indexed in Scilit:
- Predicting Post‐Mortem α‐Synuclein Pathology by the Combined Presence of Probable REM sleep behavior disorder and HyposmiaMovement Disorders Clinical Practice, 2024
- The impact of race on olfaction: A systematic review and meta‐analysisInternational Forum of Allergy & Rhinology, 2023
- Update of the MDS research criteria for prodromal Parkinson's diseaseMovement Disorders, 2019
- Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentationsMovement Disorders, 2019
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- MDS research criteria for prodromal Parkinson's diseaseMovement Disorders, 2015
- Heart rate variability and the risk of Parkinson disease: The Atherosclerosis Risk in Communities studyAnnals of Neurology, 2015
- Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)Movement Disorders, 2010
- A Clinicopathologic Study of 100 Cases of Parkinson's DiseaseArchives of Neurology, 1993
- Index for rating diagnostic testsCancer, 1950